This study also revealed that NCF2, TYK2, and DNASE1L3 could be potential targets, which may facilitate the discovery of new therapeutic approaches for SLE because several variants on those genes are strongly associated with the risk of the disease. This evidence concerns the gene DNASE1L3 and systemic lupus erythematosus.